Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Reduced by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 45.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 171,285 shares of the specialty pharmaceutical company’s stock after selling 143,816 shares during the period. JPMorgan Chase & Co.’s holdings in Supernus Pharmaceuticals were worth $8,186,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC lifted its holdings in shares of Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 268 shares during the last quarter. Arizona State Retirement System increased its holdings in Supernus Pharmaceuticals by 1.7% in the third quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock worth $791,000 after buying an additional 277 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 281 shares during the last quarter. Amalgamated Bank raised its position in Supernus Pharmaceuticals by 2.0% during the third quarter. Amalgamated Bank now owns 16,030 shares of the specialty pharmaceutical company’s stock valued at $766,000 after acquiring an additional 313 shares in the last quarter. Finally, Covestor Ltd lifted its stake in Supernus Pharmaceuticals by 29.6% in the third quarter. Covestor Ltd now owns 2,309 shares of the specialty pharmaceutical company’s stock valued at $110,000 after acquiring an additional 527 shares during the last quarter.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $49.52 on Monday. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $59.68. The company has a market cap of $2.85 billion, a PE ratio of -72.82, a price-to-earnings-growth ratio of 1.54 and a beta of 0.70. The business’s 50 day moving average is $50.99 and its two-hundred day moving average is $49.39.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Stifel Nicolaus upped their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a report on Friday, December 19th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $62.17.

Insider Activity

In other Supernus Pharmaceuticals news, Director Bethany Sensenig sold 4,475 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total transaction of $228,269.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jack A. Khattar sold 35,000 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the sale, the chief executive officer owned 958,100 shares of the company’s stock, valued at $48,259,497. This trade represents a 3.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 120,881 shares of company stock worth $6,139,356. Insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.